Linsidomine (3-morpholinosydnonimine or SIN-1[1]) is a vasodilator. It is a metabolite of the antianginal drug molsidomine and acts by releasing NO from the endothelial cells nonenzymatically. It also hyperpolarizes the cell membrane through influencing the sodium-potassium pump and thereby rendering it less responsive to adrenergic stimulation. Linsidomine injection at a dose of 1 mg produces usable erection[2] in about 70% of patients and full erection in up to 50% of patients. Linsidomine does not appear to be associated with priapism.[citation needed]
^Wen TC, Rogido MR, Moore JE, Genetta T, Peng H, Sola A (October 2005). "Cardiotrophin-1 protects cortical neuronal cells against free radical-induced injuries in vitro". Neuroscience Letters. 387 (1): 38–42. doi:10.1016/j.neulet.2005.07.018. PMID16084018.
^Lemaire A, Buvat J (June 1998). "[Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1]". Progres en Urologie. 8 (3): 388–91. PMID9689672.
^Wallace DR, Dodson S, Nath A, Booze RM (January 2006). "Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function". Synapse. 59 (1): 51–60. doi:10.1002/syn.20214. PMID16237680.